Company Overview. April Rewriting cancer treatment NASDAQ: EPZM
|
|
- Irene Hampton
- 5 years ago
- Views:
Transcription
1 Company Overview NASDAQ: EPZM Rewriting cancer treatment
2 Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company s future expectations, plans and prospects, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in drug discovery and the initiation of future clinical studies or expansion of ongoing clinical studies; availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; development progress of the Company's companion diagnostics, availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements and to achieve the goals set forth in this release; whether orphan drug designation will lead to orphan drug exclusivity or the other potential benefits of orphan drug designation for which we are eligible; other matters that could affect the availability or commercial potential of the Company's therapeutic candidates or companion diagnostics or our ability to transition to a commercial-stage enterprise; and other factors discussed in the "Risk Factors" sections of the Company's Form 10-K filed with the SEC on March 9, 2016 and in the Company's other filings from time to time with the SEC. The forward-looking statements contained in this presentation reflect the Company s current views with respect to future events, and the Company assumes no obligation to update any forward-looking statements. 2
3 5-Year Vision: Rewriting Cancer Therapy through Targeted Medicines for Patients with Unsolved Diseases Four transformative activities through 1 2 Tazemetostat launched globally in both non-hodgkin lymphoma (NHL) and genetically defined solid tumors Transitioned into commercial-stage organization Broad clinical program for tazemetostat Expanded use in earlier lines of therapy, combination regimens and multiple additional tumor types 3 Robust clinical pipeline with at least three new oncology product candidates in development Growing set of preclinical assets behind those 4 Expand our established leadership position in field of epigenetics and chromatin modifying proteins 3
4 Established Proof-of-Concept for Tazemetostat in Hematological Malignancies and Genetically Defined Solid Tumors Durable responses and acceptable safety profile observed in Phase 1 trial 56% Overall Response Rate in relapsed/refractory non-hodgkin lymphoma patients Activity across multiple NHL subtypes in heavily pre-treated relapsed/refractory population 55% Disease Control Rate in patients with genetically defined solid tumors treated at or above recommended phase 2 dose Activity in INI1-and SMARCA4-negative tumors Oral, twice-daily therapy for adults; oral suspension formulation for children Preclinical data support combination potential with multiple therapies Preclinical data support advancement into additional indications 4 *Disease Control Rate: CR, PR or SD and on drug 6 months
5 Robust Portfolio of Oncology Assets Clinical Pipeline Research and Development Pipeline NHL: non-hodgkin lymphoma DLBCL: Diffuse large B-cell lymphoma MLL-r: Mixed lineage leukemia rearranged ALL: Acute lymphoblastic leukemia AML: Acute myeloid leukemia *Eisai holds Japanese development and commercialization rights to tazemetostat **Celgene holds ex-us rights ***GSK holds global development and commercialization rights ****Celgene holds option to license ex-us rights for one target and global rights for the other two targets 5
6 Tazemetostat Acceptable Safety Profile in Phase 1 Patients (n=55) All Events All Treatment-Related All Grades * Grade >3 All Grades Grade >3 ** Asthenia Decreased appetite Thrombocytopenia Nausea Constipation Diarrhea Vomiting Anemia Dry skin Dysgeusia Dyspnea Muscle spasms Abdominal pain Hypophosphatemia Anxiety Depression Hypertension Insomnia Neutropenia Night sweats Peripheral edema Hepatocellular injury NHL patients; 35 solid tumor patients * All AEs with frequency >5% regardless of attribution shown ** All grade >3 treatmentrelated events shown 6 Source: ASH, Dec 2015, data cutoff as of Nov. 7, 2015
7 NHL Therapy Market Expected to Grow to >$9B Worldwide by ,000 estimated new patients diagnosed annually with B-cell NHL in major markets 2 EZH2mut FL 6,000 EZH2wt DLBCL 24,000 EZH2mut DLBCL 6,000 EZH2 wt FL 30,000 Non-GC DLBCL 89,000 7 GC = Germinal Center 1 GBI Research, Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020, Oct Epizyme commissioned market research
8 Best Response with Tazemetostat in NHL Patients Per Protocol: Response Evaluable* Patients (n=16) DLBCL FL MZL 5/10 (50%) 3/5 (60%) 1/1 CR+PR 9/16 (56%) DLBCL FL MZL Response evaluable: Measurable disease 1 dose 1 post-baseline scan 8 *Per Cheson/IWG Criteria (2007) Source: ASH, Dec 2015, data cutoff as of Nov. 7, 2015
9 Objective Responses Among NHL Patients Dose BID DLBCL FL MZL 9 Per Cheson/IWG Criteria (2007) Food Effects (FE): 200 mg on day -8 and day -1, 400 mg BID from day 1 Source: ASH, Dec 2015, data cutoff as of Nov. 7, 2015
10 Tazemetostat Registration-Supporting Five-Arm Phase 2 Study Underway in NHL Phase 2 Arms in Relapsed/Refractory NHL Germinal Center DLBCL wild-type EZH2 n = 30 Germinal Center DLBCL mutant EZH2 n = 30 Non-Germinal Center DLBCL -- n = 30 Follicular Lymphoma wild-type EZH2 n = 30 Follicular Lymphoma mutant EZH2 n = 30 Study design 5 arms enrolling up to 30 patients each subject to interim futility analysis for each arm Arms enroll independently Primary endpoint Overall response rate by Cheson/IWG criteria (2007) Secondary endpoints Duration of response, PFS, overall survival Global trial with accepted U.S. IND for DLBCL Presentation of interim data planned for mid-2016 Preliminary Epizyme review indicates futility has likely been surpassed in three of five arms; formal confirmation will be made by IDMC 10
11 Significant Need for Targeted Therapies in Genetically Defined Solid Tumors INI1-negative tumors: range of rhabdoid tumors, including malignant rhabdoid tumor 1 One of most aggressive and lethal malignancies in pediatric cancer Occurs most commonly in children, but also occurs in adults Treatment is non-standardized and highly toxic includes chemotherapy, radiation therapy and transplant Median survival of ~1 year 2 SMARCA4-negative tumors, including malignant rhabdoid tumor of ovary 3 Average age of onset is 24 years old Typically unresponsive to platinum-based therapies 2-year survival rate of <35% Synovial sarcoma 4 Occurs most commonly in teenagers and young adults High grade tumor that metastasizes to distant sites in 50-70% of cases 11 1 Horazdovsky R Sarcoma Reinhard, Oncology Reports, Bailey, Pediatric Blood Cancer, Krieg AH, Annals Oncology, 2010.
12 Best Response with Tazemetostat in INI1- and SMARCA4-negative Tumors * Patients censored at time of progression INI1-negative SMARCA4-negative Other solid tumor** ** Four additional other solid tumor patients with pending disease evaluation 12 Source: ESMO, Sep 2015; data cutoff as of August 31, 2015
13 Clinical Activity Seen with Tazemetostat in INI1- and SMARCA4-negative Tumors Tumor * Confirmed response by RECIST 1.1 criteria * Patients who remained on study as of Aug 31, 2015 Dose (mg BID) Best Response Time on study (weeks) INI1-negative Malignant rhadbdoid tumor 800 CR week 8* 65+ SMARCA4- negative 1600 PR week SD week SD week PD week 8 35 Epithelioid sarcoma 800 PR week Malignant rhabdoid tumor of ovary (SCCOHT) 800 SD week PD week PR week 8* SD week Thoracic sarcoma 1600 PD week Source: ESMO, Sep 2015; data cutoff as of August 31, 2015
14 Tazemetostat Registration-Supporting Program Underway in Genetically Defined Solid Tumors Adult Phase 2 N = up to 90 (30 in each arm) Rhabdoid tumors Other INI1-negative tumors Synovial sarcoma Pediatric Phase 1 N = ~ 40 INI1-negative tumors (including rhabdoid tumors) Synovial sarcoma Primary endpoint ORR for rhabdoid and other INI1-negative tumors PFS for synovial sarcoma Secondary endpoint Duration of response, PFS, OS, Safety and PK Dosing: 800 mg BID orally Global study; accepted U.S. IND Primary endpoint Safety, determine recommended Phase 2 dose Secondary endpoint ORR, Duration of response, PFS, OS, PK Dosing: Oral suspension, dose escalation Global study; accepted U.S. IND 14 Rhabdoid tumors: malignant rhabdoid tumor, rhabdoid tumor of the kidney, atypical teratoid/rhabdoid tumor Other INI1-negative tumors: epithelial sarcoma, epithelioid malignant peripheral nerve sheath tumor, extraskeletal myxoid chondrosarcoma, myoepithelial carcinoma, renal medullary carcinoma
15 Phase 2 Study in BAP1-Loss of Function Mesothelioma to Begin in 3Q16 ~12,000 incident mesothelioma patients in major pharmaceutical markets 1,2 BAP1 mutations occur in ~46% of cases 3 Approved first-line therapy, pemetrexed plus cisplatin, provides median OS of ~13 months 4 No approved therapies for second-line, response rates generally <10% 5 BAP1-loss of function mesothelioma shows sensitivity to EZH2 inhibition in xenograft models 6 BAP1-mutant BAP1 wild type Tumor fold change (Normalized to day 1) Tumor fold change (Normalized to day 1) Tumor fold change (Normalized to day 1) Tumor fold change (Normalized to day 1) 15 **P < 0.005; ns, not significant; error bars show means ± s.d. unless otherwise indicated *EPZ011989: EZH2 inhibitor 1 American Cancer Society 2 Park EK Envi Health Perspectives (2011) 3 Farzin Anatomic Pathology (2015) 4 Goudar RK Thera and Clin Risk Mgmt (2008) 5 Tsao AS JCO (2009) 6 LaFave et al., (2015) Nature Medicine
16 Advancing Robust Portfolio of Next-Generation Compounds Pioneering development of small molecule inhibitors for histone methyltransferase (HMT) and other chromatin modifying protein (CMP) targets More than 32,000 CMP inhibitors as part of large proprietary chemical library In-house discovery platform enables rapid identification of important therapeutic targets that can be effectively drugged Sophisticated use of CRISPR technology to prioritize novel targets 5 novel epigenetic targets identified small molecule inhibitors in development At least three oncology product candidates to enter clinic by
17 Collaborations with Leading Pharmaceutical and Diagnostic Companies Worldwide option on compounds against two HMT targets Ex-U.S. option on one HMT target Global collaboration on pinometostat Global development and commercialization rights to compounds against three targets, including first-in-class PRMT5 inhibitor Research collaboration completed; preclinical evaluation ongoing Collaboration to develop companion diagnostic for detection of common EZH2 gain-of-function mutations in NHL In use in ongoing phase 2 NHL study to identify patient EZH2 mutation status Development and commercialization rights to tazemetostat in Japan; right of first negotiation for rest of Asia 17
18 Multiple Clinical Milestones Anticipated throughout 2016 Upcoming Milestone Timing Initiate phase 1b/2 combination study of tazemetostat in NHL with R-CHOP 2Q 2016 Initiate combination study of tazemetostat with anti- PD1-1 or PDL-1 agent Present interim data from 5-arm phase 2 study of tazemetostat in NHL Mid-2016 Mid-2016 Initiate phase 2 study of tazemetostat in BAP1-loss of function mesothelioma 3Q 2016 Present interim data from 3-arm phase 2 study of tazemetostat in adults with genetically defined solid tumors 2H 2016 Present phase 1 pediatric pinometostat data 2H 2016 Present updated phase 2 from 5-arm phase 2 study of tazemetostat in NHL Late
19 Rewriting Cancer Therapy through Targeted Medicines for Patients with Unsolved Diseases Expansive tazemetostat clinical development program actively enrolling Multiple readouts from registration-supporting phase 2 trials of tazemetostat in 2016 Wholly owned small molecule inhibitors in development against five novel targets Top-tier pharmaceutical collaborations advancing seven programs Financial strength to fund operations through multiple value-accretive milestones 19
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationA Phase 1 Study of Tazemetostat (EPZ-6438), an Enhancer of Zeste-Homolog 2 (EZH2) Inhibitor: Preliminary Activity in INI1-Negative Tumors
A Phase 1 Study of Tazemetostat (EPZ-6438), an Enhancer of Zeste-Homolog 2 (EZH2) Inhibitor: Preliminary Activity in INI1-Negative Tumors A Italiano, H Keilhack, M Toulmonde, J-M Coindre, J-M Michot, C
More informationPersonalized Therapeutics The Power of Epigenetics. Company Overview. June 2014
Personalized Therapeutics The Power of Epigenetics Company Overview June 2014 2013 Accomplishments Forward Looking Statements This presentation contains forward-looking statements that involve substantial
More informationParticipating Institutions Insitut Gustave Roussy, Villejuif, France Institut Bergonie, Bourdeaux, France. Sponsor Epizyme, Inc
Phase 1 Study of EPZ-6438 (E7438), an Enhancer of Zeste Homolog-2 (EZH2) Inhibitor: Dose Determination and Preliminary Activity in Non-Hodgkin Lymphoma V. Ribrag, J-C. Soria, B. Thomson, L. Reyderman,
More informationCiti 10 th Annual Biotech Conference! September 9, 2015!!
Citi 10 th Annual Biotech Conference! September 9, 2015!! Forward Looking Statements! Any statements in this presentation about future expectations, plans and prospects for Epizyme, Inc. and other statements
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationTARGETING EZH2 WITH TAZEMETOSTAT IN FOLLICULAR LYMPHOMA
TARGETING EZH2 WITH TAZEMETOSTAT IN FOLLICULAR LYMPHOMA VINCENT RIBRAG Chairman hematological multidisciplinary committee Ditep (chief molecular therapeutics in hematological early drug development) Bologna
More informationNASDAQ: TGTX Jefferies Healthcare Conference June 2015
NASDAQ: TGTX Jefferies Healthcare Conference June 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationActinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationNASDAQ: TGTX. 33 rd Annual JP Morgan Healthcare Conference
NASDAQ: TGTX 33 rd Annual JP Morgan Healthcare Conference January 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities
More informationMANIFEST Phase 2 Enhancement / Expansion
MANIFEST Phase 2 Enhancement / Expansion Investor Conference Call Stellar Science, Breakthrough Medicine October 11, 2018 Forward-Looking Statements This presentation contains forward-looking statements
More informationARQ 087 Overview. FGFR Inhibitor. March 2017
ARQ 087 Overview FGFR Inhibitor March 2017 Safe Harbor This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationBuilding a Leading Oncology Franchise
ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may
More informationNY-ESO SPEAR T-cells in Synovial Sarcoma
NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationInternational Conference on Malignant Lymphoma (ICML) June 14-17, 2017
International Conference on Malignant Lymphoma (ICML) June 14-17, 2017 INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR: CLINICAL ACTIVITY AND FAVORABLE SAFETY IN PATIENTS
More informationKaryopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
August 10, 2015 Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress - Positive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers - - Provides
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationCapricor Therapeutics
Therapeutics Conference Call to Discuss the HOPE-2 Clinical Trial NASDAQ: CAPR November 29, 2017 Forward-Looking Statements Statements in this presentation regarding the efficacy, safety, and intended
More informationMyeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients
December 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationCorporate Presentation June Curis, Inc All Rights Reserved
Corporate Presentation June 2018 Curis, Inc. 2018 All Rights Reserved Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ( we, us, or the Company
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationNeedham Healthcare Conference. April 4, 2017
Needham Healthcare Conference April 4, 2017 Forward Looking Statements This presentation and various remarks we make during this presentation contain forward-looking statements within the meaning of The
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationTarGeting B-Cell Diseases
TarGeting B-Cell Diseases Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements
More information-- Single Global Phase 3 Trial Expected to Begin in First Half of
Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment -- Consistent
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationFOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019
FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationCowen Annual Healthcare Conference. March 2018
Cowen Annual Healthcare Conference March 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationBuilding Shareholder Value
Building Shareholder Value June 4, 2014 Jefferies Healthcare Conference Tim Clackson, Ph.D. Hans Loland P r e s i d e n t o f R & D, C h i e f S c i e n t i f i c O f f i c e r with wife Cynthia A R I
More information-- Edasalonexent Substantially Slowed Duchenne Muscular Dystrophy Disease Progression through 36 Weeks --
Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial
More informationJanssen Hematologic Malignancy Portfolio
Janssen Hematologic Malignancy Portfolio Recorded Webcast: Update for Analysts and Investors January 216 Oncology 1 Safe Harbor Statement This webcast contains "forward-looking statements" as defined in
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationForward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements related to Seattle Genetics corporate priorities, financial guidance and anticipated upcoming activities,
More informationFORWARD II PROGRAM UPDATE
FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,
More informationASH POSTER: LYMRIT UPDATE
ASH POSTER: LYMRIT 37-01 UPDATE DECEMBER 2018 EDUARDO BRAVO, CEO LISA ROJKJAER, MD, CMO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com IR contact: ir@nordicnanovector.com
More informationPfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer
For immediate release June 3, 2017 Media Contact: Sally Beatty (212) 733-6566 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib
More informationBuilding a Leading Oncology Franchise
Building a Leading Oncology Franchise January 2019 NASDAQ: MEIP Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are
More informationPharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765
Contact: Ramses Erdtmann Vice President of Finance Phone: 408-215-3325 Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Company to Host
More informationESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE
ESMO 2016 * Investor Meeting October 9, 2016 *European Society of Medical Oncology, October 7-11, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future
More informationStifel Healthcare Conference John Scarlett, M.D. Chief Executive Officer November 19, 2014
Stifel Healthcare Conference 2014 John Scarlett, M.D. Chief Executive Officer November 19, 2014 1 forward-looking statements Except for statements of historical fact, the statements during this presentation
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationLonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015
Lonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015 Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are
More informationCorporate Presentation. Curis, Inc All Rights Reserved
Corporate Presentation Curis, Inc. 2018 All Rights Reserved Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ( we, us, or the Company ) within
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationDisrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference
CYC 682 Disrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference September 2014 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor
More informationJefferies Healthcare Conference. June 25, 2008
Jefferies Healthcare Conference June 25, 2008 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationPSMA-617 License Transaction. October 2, 2017
PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More information[ NASDAQ: MEIP ] Cowen and Company Health Care Conference March 2015
[ NASDAQ: MEIP ] Cowen and Company Health Care Conference March 2015 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationPath to Value and Profitability
Path to Value and Profitability June 4, 2015 Tim Clackson, Ph.D. President of R&D, Chief Scientific Officer ARIAD Pharmaceuticals, Inc. Elsa So Non-small cell lung cancer ARIAD clinical trial patient Some
More information[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014
[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer
ALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer Dr. Ben Solomon Medical Oncologist, Thoracic Oncology Peter MacCallum Cancer Centre Melbourne, Australia Dr. D.
More informationDELIVERING NEXT-GENERATION RADIO-IMMUNOTHERAPIES FOR LYMPHOMA PATIENTS
DELIVERING NEXT-GENERATION RADIO-IMMUNOTHERAPIES FOR LYMPHOMA PATIENTS DNB SME CONFERENCE 4 TH APRIL, 2019 EDUARDO BRAVO, CEO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 1Q 2018 EARNINGS PRESENTATION MAY 2018 1 Forward-looking statements disclosure This presentation contains
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationTumor Antigens in the Age of Engineered T cell Therapies
Tumor Antigens in the Age of Engineered T cell Therapies September 30 th 2016 ESMO Preceptorship Course Amsterdam Carsten Linnemann, PhD Senior Scientist Kite Pharma EU B.V. Amsterdam Forward Looking Statements/Safe
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More informationGenta Incorporated. A Multiproduct Late-Stage Oncology Company
Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking
More information2008 Bank of America Health Care Conference May 2008
2008 Bank of America Health Care Conference May 2008 NASDAQ: ALTH -1- Safe Harbor Statement This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationNEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationPRO 140. First self-administered antibody therapy for HIV in late-stage clinical development. March
PRO 140 First self-administered antibody therapy for HIV in late-stage clinical development March 2018 Forward-Looking Statements This presentation includes forward-looking statements and forward-looking
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More information